✦ LIBER ✦

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer

✍ Scribed by Chih-Hsin Yang; Jin-Yuan Shih; Kun-Chieh Chen; Chong-Jen Yu; Tsung-Ying Yang; Ching-Pei Lin; Wen-Pin Su; Chien-Hung Gow; Chiun Hsu; Gee-Chen Chang; Pan-Chyr Yang

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 212 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22220

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 trial of everolimus and gefitini

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer

✍ Daniel T. Milton; Gregory J. Riely; Christopher G. Azzoli; Jorge E. Gomez; Rober 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 3 views

## Abstract ## BACKGROUND. Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dos

Epidermal growth factor receptor mutatio

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

✍ Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Me 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB 👁 2 views

## Abstract Recently, mutations in the __epidermal growth factor receptor__ (__EGFR__) gene in nonsmall cell lung cancer (NSCLC) patients were reported to correlate with gefitinib response. Less than 30% of NSCLC patients are surgically resectable; however, molecular analysis has to rely on nonsurg

Comparative analysis of epidermal growth

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

✍ Takashi Sone; Kazuo Kasahara; Hideharu Kimura; Kazuto Nishio; Masayuki Mizuguchi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB 👁 1 views

## Abstract ## BACKGROUND. Because the investigation of epidermal growth factor receptor gene (__EGFR__) status as a predictor of gefitinib efficacy in Japanese patients has shown promise, the authors evaluated __EGFR__ mutations and gene amplification in biopsy specimens from Japanese patients wi

Recent improvement in the survival of pa

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Alessandra Bearz; Diego Serraino; Lucia Fratino; Massimiliano Berretta; Umberto 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 3 views

A recent article by Hotta and colleagues 1 reports that survival of patients with nonsmall cell lung cancer (NSCLC) improved slowly over time from 1982 to 2002. Authors pooled together 121 phase 3 trials (42,768 patients overall),

Recent improvement in the survival of pa

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Katsuyuki Hotta; Yoshiro Fujiwara; Keitaro Matsuo; Takeshi Suzuki; Katsuyuki Kiu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB 👁 3 views

Final survival and safety results from a

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

✍ David R. Spigel; Ming Lin; Vincent O'Neill; John D. Hainsworth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

## Abstract ## BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth factor receptor (EGFR) with a proven survival advantage for patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) who have failed a prior chemotherapy. This phase 3b, mult